MARCOS
GONZÁLEZ DÍAZ
Investigador en el periodo 1993-2023
Mar
Tormo Díaz
Publicaciones en las que colabora con Mar Tormo Díaz (12)
2020
-
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica, Vol. Online ahead of print
2011
-
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens
Blood, Vol. 117, Núm. 6, pp. 1799-1805
2010
-
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
Haematologica, Vol. 95, Núm. 3, pp. 424-431
-
Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial
Haematologica, Vol. 95, Núm. 1, pp. 87-95
2009
-
Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis
Haematologica, Vol. 94, Núm. 9, pp. 1242-1249
-
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors
Blood, Vol. 113, Núm. 4, pp. 775-783
2008
2007
-
Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): Benefit of an early intervention
Leukemia, Vol. 21, Núm. 3, pp. 446-452
-
Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia
British Journal of Haematology, Vol. 136, Núm. 4, pp. 590-596
-
Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies
Leukemia, Vol. 21, Núm. 7, pp. 1413-1422
2001
-
Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracycline-based protocol. A report from the spanish group PETHEMA
Haematologica, Vol. 86, Núm. 8, pp. 807-813
-
Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms: A study of the PETHEMA group
British Journal of Haematology, Vol. 114, Núm. 1, pp. 99-103